JEMPERLI was studied in the largest single-agent immunotherapy trial data set in endometrial cancer, GARNET1-3

Global, multicenter, multiple cohort, open-label study1

  • JEMPERLI: 500 mg every 3 weeks for 4 doses, followed by 1000 mg every 6 weeks1*

Patient Population1

  • Recurrent or advanced endometrial cancer that had progressed on or following treatment with a platinum-containing regimen
  • Tumors that were mismatch repair deficient as determined by IHC testing. The dMMR tumor status was retrospectively confirmed using the VENTANA MMR RxDx Panel assay


150 patients


141 patients

Primary Efficacy Endpoints1

  • Overall response rate (ORR)
  • Duration of response (DOR)


Treatment continued until disease progression or unacceptable toxicity.1

As assessed by blinded independent central review (BICR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.1

Key Inclusion and Exclusion Criteria1,3

GARNET Cohort A1: dMMR endometrial cancer

Inclusion criteria

  • Recurrent or advanced endometrial cancer
  • dMMR endometrial cancer as determined by IHC testing
  • Progression on or after platinum-containing regimen
  • ≤2 lines of prior anticancer treatment for recurrent or advanced disease

Exclusion criteria

  • Prior treatment with PD-1/PD-L1–blocking antibodies or other immune checkpoint inhibitor therapy
  • Autoimmune disease that required systemic treatment within 2 years

89% of patients had received prior anticancer surgery and 71% had received prior anticancer radiotherapy. Approximately 37% of patients had 2 lines or more of prior anticancer treatment in total.1

dMMR=mismatch repair deficient; IHC=immunohistochemistry; PD-1=programmed death receptor 1; PD-L1=programmed death ligand 1.

GARNET Cohort A1: Patient baseline characteristics1,4

Efficacy population baseline characteristics (n=141)1

  • Of the 150 patients in the study with dMMR endometrial cancer who received JEMPERLI, 141 were included in the efficacy analysis

JEMPERLI (dostarlimab-gxly) Clinical Trial Baseline Characteristics for GARNET Endometrial Cancer Cohort in the updated analysis

ECOG=Eastern Cooperative Oncology Group; NOS = not otherwise specified.

Icon: JEMPERLI (dostarlimab-gxly) Response Rate

Learn about response with

Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety profile 
and tolerability of JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.